Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Haleon PLC ( (GB:HLN) ) has provided an update.
Haleon plc has repurchased 5,266,782 ordinary shares for cancellation under its ongoing share buyback programme, with purchases executed between 30 March and 2 April 2026 across the London Stock Exchange and multiple alternative trading venues. Following these transactions, the company’s registered share capital stands at 8,927,564,553 ordinary shares, of which 12,493,360 are held in treasury, leaving 8,915,071,193 shares with voting rights.
The reduction in Haleon’s free‑float through cancellations marginally increases existing shareholders’ proportional ownership and may support earnings per share over time, signalling continued confidence in the company’s financial position. The updated share count also provides an important reference point for investors monitoring disclosure thresholds under U.K. transparency rules and assessing Haleon’s capital allocation strategy within the consumer health sector.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon plc is a global consumer health company focused on improving everyday health through a portfolio spanning oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health and therapeutic skin care. Its leading brands, including Advil, Centrum, Panadol, Sensodyne and Voltaren, reach more than a billion consumers worldwide and are frequently recommended by health professionals.
Average Trading Volume: 19,829,186
Technical Sentiment Signal: Buy
Current Market Cap: £33.25B
Learn more about HLN stock on TipRanks’ Stock Analysis page.